Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
3.650
-0.280 (-7.12%)
Jun 18, 2025, 4:00 PM - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 41 employees as of December 31, 2024. The number of employees increased by 10 or 32.26% compared to the previous year.
Employees
41
Change (1Y)
10
Growth (1Y)
32.26%
Revenue / Employee
n/a
Profits / Employee
-$1,215,390
Market Cap
94.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CTNM News
- 5 weeks ago - Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference - Business Wire
- 5 weeks ago - Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 7 weeks ago - Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - Business Wire
- 3 months ago - Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - Business Wire
- 3 months ago - Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum - Business Wire
- 3 months ago - Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 3 months ago - Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 - Business Wire
- 3 months ago - Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference - Business Wire